Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Rating of “Moderate Buy” from Analysts

Twist Bioscience Co. (NASDAQ:TWST) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $51.90.

A number of research firms recently commented on TWST. Robert W. Baird increased their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at approximately $2,034,652. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,640 shares of company stock valued at $4,123,772. 3.92% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Geode Capital Management LLC lifted its stake in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after acquiring an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter valued at $43,992,000. Wellington Management Group LLP grew its position in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Finally, Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after purchasing an additional 112,272 shares during the last quarter.

Twist Bioscience Trading Down 1.9 %

Shares of Twist Bioscience stock opened at $42.75 on Wednesday. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of -11.88 and a beta of 1.85. The firm’s 50-day moving average price is $46.43 and its two-hundred day moving average price is $46.38. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.